Gabapentin Solution
Product Images NDC 81033-124

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 81033-124). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Kesin Pharma Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin Oral Solution 5 mL 40 Ct Carton Label (Gabapentin Os 5ml 40ct Carton)

Label for Gabapentin Oral Solution 250 mg per 5 mL, in unit dose cups. Packaged and distributed by Kesin Pharma Corporation, Oldsmar, FL. Contains 40 x 5 mL unit dose cups, for institutional use only, requiring refrigeration between 36°F to 46°F (2°C to 8°C). The label includes NDC 81033-123-44 and barcode information.*

FDA Label Image

Gabapentin Oral Solution 6 mL 40 Ct Carton Label (Gabapentin Os 6ml 40ct Carton)

Gabapentin Oral Solution 300 mg per 6 mL label showing dosage form as oral solution. The label states the package contains 40 unit dose cups of 6 mL each and is distributed by Kesin Pharma Corporation, Oldsmar, FL. Storage instructions specify refrigeration between 36°F to 46°F (2°C to 8°C). The label is marked for institutional use only and Rx Only.*

FDA Label Image

Kesin Pharma Logo (Kesin Logo)

FDA Label Image

Kesin Pharma Logo (Kesin Logo)

FDA Label Image

Formula (Gabapentin Oral Solution 1)

A formula calculation for creatinine clearance (CLCr) involving age, weight, serum creatinine, and a factor for female patients. This text likely appears in clinical or dosing instructions related to evaluating kidney function.*

FDA Label Image

Structure (Gabapentin Oral Solution 2)

Chemical structure of gabapentin showing a cyclohexane ring connected to an amino group (CH2NH2) and a carboxyl group (CH2CO2H).*

FDA Label Image

Diagram1 (Gabapentin Oral Solution 3)

A line graph displaying mean pain scores over an 8-week period comparing placebo and gabapentin 3600 mg/day. The x-axis shows weeks divided into a 4-week dose titration and a 4-week fixed dose period, while the y-axis shows mean pain scores ranging from 0 to 9. Gabapentin scores decline steadily, lower than placebo scores which remain relatively stable.*

FDA Label Image

Diagram2 (Gabapentin Oral Solution 4)

A line graph showing mean pain scores over a 7-week period comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis is labeled with weeks including baseline, and the y-axis shows mean pain score from 0 to 10. The graph distinguishes a 3-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Diagram3 (Gabapentin Oral Solution 5)

This bar chart compares the outcomes of two studies evaluating different dosages of Gabapentin (GBP) oral solution against placebo (PBO). Study 1 shows 12% for placebo and 29% for GBP 3600 mg, while Study 2 shows 14% for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance is indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

Diagram4 (Gabapentin Oral Solution 6)

A scatter plot showing the percentage difference versus daily dose (mg) from three studies labeled as Study a, Study b, and Study c. The x-axis represents daily dose ranging from 600 to 1800 mg, and the y-axis represents difference in percentage from 2% to 22%. Data points from each study are plotted with distinct symbols, illustrating variation in difference percentages across doses.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.